Company ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Chiffre d''affaires - Rate of surprise

Sector Bio Therapeutic Drugs

IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.

Market Closed - Hong Kong S.E. Other stock markets 04:08:07 2024-05-09 am EDT			5-day change	1st Jan Change
14.9 ^HKD	-0.53%		+1.09%	-50.17%

Apr. 17	ImmuneOnco Obtains Chinese Nod for Phase III Trials of Anti-Cancer Medication	MT
Apr. 17	ImmuneOnco Biopharmaceuticals Inc. Receives Approval from the National Medical Products Administration of the People's Republic of China for the Protocol of the Phase Iii Clinical Trial of IMM01	CI

ImmuneOnco Biopharmaceuticals Shanghai Inc is a China-based company mainly engaged in research and development of testing biotechnology. The Company's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The Company mainly operates its businesses in the domestic and overseas markets.

Number of employees: 145

HKD in Million	2022	Weight	2023	Weight	Delta
Cell Strain and Other Products 95.1 %	1	92.8 %	0	95.1 %	-30.11%
Testing Services 4.9 %	0	7.2 %	0	4.9 %	-53.71%

HKD in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	1	100.0 %	0	100.0 %	-31.82%

Managers	Title	Age	Since
Wen Zhi Tian CEO	Chief Executive Officer	-	15-05-31
Qi Ying Lu CTO	Chief Tech/Sci/R&D Officer	-	22-02-28
Song Li CTO	Chief Tech/Sci/R&D Officer	-	15-11-30
Zikai Xiong PRN	Corporate Officer/Principal	-	22-02-28
Ru liang Zhang PRN	Corporate Officer/Principal	-	17-01-31

Members of the board	Title	Age	Since
Chi Tat Yeung BRD	Director/Board Member	55	-
Zhi Hua Yu BRD	Director/Board Member	56	-
Wen Zhi Tian CEO	Chief Executive Officer	-	15-05-31
Zhenping Zhu BRD	Director/Board Member	-	-
Xiao Yong Yu BRD	Director/Board Member	51	-
Song Li CTO	Chief Tech/Sci/R&D Officer	-	15-11-30
Cong Xu BRD	Director/Board Member	-	-
Kendall Smith BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	228,550,039	69,612,628 ( 30.46 %)	0	30.46 %

Name	Equities	%	Valuation
Wen Zhi Tian 15.35 %	35,091,495	15.35 %	72 M $
LAV Management Co., Ltd. 12.13 %	27,721,575	12.13 %	57 M $
Halo Biomedical LP 7.876 %	18,000,000	7.876 %	37 M $
Yi Quan Cheng 7.246 %	16,560,270	7.246 %	34 M $
Greater Bay Area Homeland Investments Ltd. 6.062 %	13,854,690	6.062 %	29 M $
Zhouling Private Equity Fund Management (Shanghai) Co., Ltd. 5.254 %	12,008,757	5.254 %	25 M $
Shanghai Pudong State-owned Asset Supp & Mgmt Commission 4.753 %	10,862,055	4.753 %	22 M $
Jiaxing Changxian Enterprise Management LP 3.395 %	7,758,630	3.395 %	16 M $
Jiaxing Changyu Enterprise Management LP 3.246 %	7,419,848	3.246 %	15 M $
Jiaxing Zhangke Lingyi Siqi Equity Investment Partnership Lp 2.430 %	5,554,305	2.430 %	11 M $

Name	Equities	%	Valuation
LAV Management Co., Ltd. 100.00 %	7,967,925	100.00 %	16 M $

Name	Equities	%	Valuation
Shanghai Zhangjiang Leading Initiating Venture Capital LP 25.26 %	36,780,390	25.26 %	76 M $
Wen Zhi Tian 24.10 %	35,091,495	24.10 %	72 M $
Zhi Hua Yi 13.23 %	19,263,240	13.23 %	40 M $
LAV Management Co., Ltd. 5.472 %	7,967,925	5.472 %	16 M $
Jiaxing Changxian Enterprise Management LP 5.328 %	7,758,630	5.328 %	16 M $
Jiaxing Changyu Enterprise Management LP 5.096 %	7,419,847	5.096 %	15 M $
Zhouling Private Equity Fund Management (Shanghai) Co., Ltd. 2.749 %	4,002,918	2.749 %	8 M $

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd.

Building 15, Lane 1000 Zhangheng Road

200120, Zhangjiang Science City

+86 21 3801 6387

http://cn.immuneonco.com

address ImmuneOnco Biopharmaceuticals (Shanghai) Inc.(1541)

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

13.85 CNY

Average target price

15.13 CNY

Spread / Average Target

+9.27%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.	-50.17%	717M
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	108B
ARGENX SE	-1.46%	23.46B
BIONTECH SE	-14.60%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-38.55%	17.45B
BEIGENE, LTD.	-8.83%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	13.99B
SAREPTA THERAPEUTICS, INC.	+37.49%	12.53B
VIKING THERAPEUTICS, INC.	+329.39%	8.81B

Bio Therapeutic Drugs